Notably, mutations in the PTEN phosphatase domain were significantly associated with shorter survival and the presence of an immunosuppressive tumor microenvironment in MSI-H/dMMR gastrointestinal tumors patients treated with anti-PD-1 therapy (11). This evidence concerns the gene PTEN and digestive system neoplasm.